Skip to main content
. Author manuscript; available in PMC: 2014 May 7.
Published in final edited form as: Nature. 2013 Oct 9;503(7474):126–130. doi: 10.1038/nature12614

Figure 3. A panspecific transforming growth factor β-neutralizing antibody reverses established skin fibrosis.

Figure 3

(A) Clinical assessment showing that stiffness was fully normalized by TGFβ-neutralizing antibody (TGFβNAb) treatment, commencing at three months of age and lasting twelve weeks. (B) Histologic and morphometric analyses using Masson’s trichrome stain. Isotype control-treated: n = 14 (Fbn1+/+), 9 (Fbn1D1545E/+), 8 (Fbn1W1572C/+). TGFβNAb-treated: n = 14 (Fbn1+/+); 10 (Fbn1D1545E/+); 8 (Fbn1W1572C/+). DE = D1545E. WC = W1572C. Scale bars, 50 µm. * p<0.05, ** p<0.01, † p<0.001, ‡ p<0.0001.